%%Post image thumbnail below.%%  > [!info|flex bg-c-gray] Episode Overview > > - **Date Aired:** [[01-13-2024]] > - **Title:** Peter Daszak Returns > - **Episode:** 279 > - **Description:** Peter Daszak is back and hosting panels at [[World Health Organization]] conferences. > - **Link:** <https://rumble.com/v46uxhb-big-dig-energy-279-peter-daszak-returns.html> %%<https://historydraft.com/happened/what-happened/1-January/world>%% ## Replay %% Get embed URL then highlight and hit ALT + I%% <iframe src="https://rumble.com/embed/v449lp8/?pub=6eeyh" allow="fullscreen" allowfullscreen="" style="height:100%;width:100%; aspect-ratio: 16 / 9; "></iframe> <br> ## Greetings & Announcements 1. I'll be on Simpcast on January 21st. 2. I uploaded The Insurrectionist Next Door to Odysee, [if you'd like to watch it](https://odysee.com/@SomeBitchIKnow:0/The-Insurrectionist-Next-Door:c). <iframe src="https://odysee.com/$/embed/@SomeBitchIKnow:0/The-Insurrectionist-Next-Door:c?r=GSuUFDTeMAgKXr6FKP1Xnu5a6Myac1KG/" allow="fullscreen" allowfullscreen="" style="height:100%;width:100%; aspect-ratio: 16 / 9; "></iframe> 1. I am having ongoing issues with my GPU. I tried a temporary fix a while back, which turned out to be, big shock, temporary. I ordered a new one, which will be here on Wednesday. I should be able to squeeze out two more shows with the one I have, but if for some reason I end up needing to cut tonight's show short, or Tuesday's show, that's why. Thanks! **(And a profound thank you to all of you who donate, because you literally keep the show running and I appreciate it more than you know. <3)** ## Segments **Main Sources:** - [Index of WHO Documents](https://www.who.int/publications/m?publishingoffices=bebe2ad5-6e24-43ed-a467-6329b4efe614) - [EcoHealth Alliance LinkedIn](https://www.linkedin.com/company/ecohealth-alliance/) ### WHO R&D Blueprint [Post](https://archive.is/c4d75) from EcoHealth Alliance on [[LinkedIn]]:  #### How it Started **[December 8-9, 2015:](https://web.archive.org/web/20200421003232/https://www.who.int/news-room/events/detail/2015/12/08/default-calendar/december-2015---first-list-of-top-emerging-diseases-likely-to-cause-major-epidemics)**  > A panel of scientists and public health experts convened by WHO met in Geneva this week to prioritise the top five to ten emerging pathogens likely to cause severe outbreaks in the near future, and for which few or no medical countermeasures exist. These diseases will provide the basis for work on the WHO Blueprint for R&D preparedness to help control potential future outbreaks. > > The initial list of disease priorities needing urgent R&D attention comprises: Crimean Congo haemorrhagic fever, Ebola virus disease and Marburg, Lassa fever, MERS and SARS coronavirus diseases, Nipah and Rift Valley fever. The list will be reviewed annually or when new diseases emerge. > > This priority list forms the backbone of the new WHO Blueprint for R&D preparedness by focusing accelerated R&D on dangerous pathogens which are the most prone to generate epidemics. As well as advocating for the initiation or enhancement of the R&D process to develop diagnostics, vaccines and therapeutics for the five to ten diseases, the Blueprint will also consider behavioural interventions, and filling critical gaps in scientific knowledge to allow the design of better disease control measures. > > The group of experts who developed the list represented a range of disciplines, including virology, microbiology, immunology, public health, clinical medicine, mathematical and computational modelling, product development, and respiratory and severe emerging infections. The conclusions of the experts were reviewed by the Blueprint's independent Scientific Advisory Group. > > Future action in this area includes fine-tuning of the prioritization methodology and the development of practical tools to assess any new diseases that may emerge. > > Three other diseases were designated as 'serious', requiring action by WHO to promote R&D as soon as possible; these were chikungunya, severe fever with thrombocytopaenia syndrome, and Zika. > > Other diseases with epidemic potential - such as HIV/AIDS, Tuberculosis, Malaria, Avian influenza and Dengue - were not included in the list because there are major disease control and research networks for these infections, and an existing pipeline for improved interventions. [PDF Link](https://ia601303.us.archive.org/2/items/blueprint-for-r-d-preparedness-and-response-meeting-report/blueprint-for-r-d-preparedness-and-response-meeting-report.pdf) <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://ia601303.us.archive.org/2/items/blueprint-for-r-d-preparedness-and-response-meeting-report/blueprint-for-r-d-preparedness-and-response-meeting-report.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[Original Scientific Advisory Group:](https://ia601306.us.archive.org/27/items/sag-members/sag-members.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://ia601306.us.archive.org/27/items/sag-members/sag-members.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[First WHO Page:](https://web.archive.org/web/20200206013420/https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)**  > **Prioritizing diseases for research and development in emergency contexts** > > For the purposes of the R&D Blueprint, WHO has developed a special tool for determining which diseases and pathogens to prioritize for research and development in public health emergency contexts. This tool seeks to identify those diseases that pose a public health risk because of their epidemic potential and for which there are no, or insufficient, countermeasures. The diseases identified through this process are the focus of the work of R& D Blueprint. > > The first list of prioritized diseases was released in December 2015. Using a published prioritization methodology  (2016), the list was first reviewed in January 2017 and a second time in 2018. An updated methodology and a new list are anticipated before the end of 2019. The Blueprint list of priority diseases is not an exhaustive list, nor does it indicate the most likely causes of the next epidemic: > > • Crimean-Congo haemorrhagic fever (CCHF) > > • Ebola virus disease and Marburg virus disease > > • Lassa fever > > • Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS) > > • Nipah and henipaviral diseases > > • Rift Valley fever (RVF) > > • Zika > > • Disease X *(Disease X represents the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease, and so the R&D Blueprint explicitly seeks to enable cross-cutting R&D preparedness that is also relevant for an unknown "Disease X" as far as possible)* **[First Blueprint:](https://cdn.who.int/media/docs/default-source/blue-print/an-randd-blueprint-for-action-to-prevent-epidemics.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/blue-print/an-randd-blueprint-for-action-to-prevent-epidemics.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[2017 Review](https://ia801303.us.archive.org/0/items/paper-prepared-by-the-who-secretariat-for-the-global-coordination-mechanism-on-r-d_202401/paper-prepared-by-the-who-secretariat-for-the-global-coordination-mechanism-on-r-d.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://ia801303.us.archive.org/0/items/paper-prepared-by-the-who-secretariat-for-the-global-coordination-mechanism-on-r-d_202401/paper-prepared-by-the-who-secretariat-for-the-global-coordination-mechanism-on-r-d.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[2017 Update:](https://cdn.who.int/media/docs/default-source/blue-print/an-randd-blueprint-for-action-to-prevent-epidemics-update-2017.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/blue-print/an-randd-blueprint-for-action-to-prevent-epidemics-update-2017.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[2018 R&D Governance on Experimental Therapeutics for Ebola](https://cdn.who.int/media/docs/default-source/ebola/summary-deliberations-ebola-therapeutics.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/ebola/summary-deliberations-ebola-therapeutics.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[January 2019 Workshop on Ebola Vaccines](https://cdn.who.int/media/docs/default-source/blue-print/ebola-vaccine-meeting-report.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/blue-print/ebola-vaccine-meeting-report.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[January 10, 2020: Teleconference on Covid](https://cdn.who.int/media/docs/default-source/blue-print/gcm-teleconference-on-pneumonia-of-unknown-etiology-in-wuhan-china-note-for-the-records-10-january-2020a391a13f06574e2a9960fd67b8271ac1.pdf?sfvrsn=c70a345f_1&download=true)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/blue-print/gcm-teleconference-on-pneumonia-of-unknown-etiology-in-wuhan-china-note-for-the-records-10-january-2020a391a13f06574e2a9960fd67b8271ac1.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[January 17, 2020: Outline of designs for experimental vaccines and therapeutics](https://cdn.who.int/media/docs/default-source/blue-print/outline-of-designs-for-experimental-vaccines-and-therapeutics.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/blue-print/outline-of-designs-for-experimental-vaccines-and-therapeutics.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[February 2020 R&D Blueprint for Covid Vaccines](https://cdn.who.int/media/docs/default-source/blue-print/wg-on-vaccine-prioritization-tors_composition_update.pdf)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/blue-print/wg-on-vaccine-prioritization-tors_composition_update.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> #### November 2022: WHO to Identify Pathogens that Could Cause Future Outbreaks and Pandemics > **[Archive](http://archive.today/amKwk)** > > WHO is launching a global scientific process to update the list of priority pathogens—agents that can cause outbreaks or pandemics—to guide global investment, research and development (R&D), especially in vaccines, tests and treatments. > > Starting with a meeting held last Friday, 18 November, WHO is convening over 300 scientists who will consider the evidence on over 25 virus families and bacteria, as well as "[[Disease X]]." Disease X is included to indicate an unknown pathogen that could cause a serious international epidemic. The experts will recommend a list of priority pathogens that need further research and investment. The process will include both scientific and public health criteria, as well as criteria related to socioeconomic impact, access, and equity. > > The list was first published in 2017 and the last prioritization exercise was done in 2018. The current list includes [[COVID-19]], Crimean-Cong hemorrhagic fever, Ebola virus disease and Marburg virus disease, Lassa fever, Middle East respiratory syndrome ([[MERS]]) and Severe Acute Respiratory Syndrome ([[SARS]]), Nipah and henipaviral diseases, Rift Valley fever, Zika and Disease X. > > "Targeting priority pathogens and virus families for research and development of countermeasures is essential for a fast and effective epidemic and pandemic response. Without significant R&D investments prior to the COVID-19 pandemic, it would not have been possible to have safe and effective vaccines developed in record time," said Dr Michael Ryan, Executive Director of WHO's Health Emergencies Program. > > For those pathogens identified as priority, the WHO R&D Blueprint for epidemics develops R&D roadmaps, which lay out knowledge gaps and research priorities. Where relevant, target product profiles, which inform developers about the desired specifications for vaccines, treatments and diagnostic tests, are developed. Efforts are also made to map, compile and facilitate clinical trials to develop these tools. Complimentary efforts – such as to strengthen regulatory and ethics oversight – are also considered. > > "This list of priority pathogens has become a reference point for the research community on where to focus energies to manage the next threat," said Dr Soumya Swaminathan, WHO Chief Scientist. "It is developed together with experts in the field, and is the agreed direction for where we—as a global research community—need to invest energy and funds to develop tests, treatments and vaccines. We thank our donors like the US government, our partners, and the scientists who work with WHO to make this possible." #### March 15, 2023: WHO Seeks out "Expert Panel" > **[Archive](https://archive.is/1IJIn)** > > **Background** > > WHO has launched a global scientific process to update its list of priority pathogens that can cause severe outbreaks or pandemics. To support this effort, the WHO Secretariat is constituting independent group of experts for the following viral families: Adenoviridae; Anelloviridae; Arenaviridae; Astroviridae; Bornaviridae; Bunyaviridae; Caliciviridae; Coronaviridae; Filoviridae; Flaviviridae; Hepadnaviridae; Hepeviridae; Herpesviridae; Orthomyxoviridae; Papillomaviridae; Paramyxoviridae; Parvoviridae; Picobirnaviridae; Picornaviridae; Pneumoviridae; Polyomaviridae; Poxviridae; Reoviridae; Retroviridae; Rhabdoviridae; and Togaviridae. > > It is expected that over 300 experts will be convened to consider the science and evidence on viruses in these 26 viral families. Each Viral Family group convened will be tasked with > > - Reviewing the proposed prioritization methodology and criteria; > - Completing online questionnaires for screening and prioritizing viruses within the family; > - Shortlisting priority and prototype pathogens within each family and making recommendations on pathogen X. > - The work is to be done remotely with at least two online interactions representing between 5-6 day of work over a 3 month period. > > **Expertise needed** > > Viral Family groups are expected to be composed of members with the following expertise: > > - Microbiology of severe diseases (including virology) > - Clinical management of severe infections > - Epidemiology and evolutionary biology (transmission) > - Animal health including veterinarians, expert in zoonoses from both livestock and wildlife  #### October 2023: Global Research and Innovation for Health Emergencies Paper [Link](https://cdn.who.int/media/docs/default-source/documents/r-d-blueprint-meetings/global-research-and-innovation-for-health-emergencies_report-2023.pdf) <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/documents/r-d-blueprint-meetings/global-research-and-innovation-for-health-emergencies_report-2023.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> #### 2024 Meetings **[January 9, 2024:](http://archive.today/fpNTj) A scientific framework for epidemic and pandemic research preparedness** > Scientific opportunities to achieve fast and equitable access to high-quality and trusted vaccines for future pandemics. > > **Background** > > Since 2015, the WHO has implemented a comprehensive global research strategy and preparedness plan known as the WHO R&D Blueprint for Epidemics. A centerpiece of this work is the WHO pathogen priority list, which ensures research efforts are concentrated on diseases with epidemic or pandemic potential where medical countermeasures and limited or non-existent. Since November 2022, a new approach has been implemented, focusing on entire classes of viruses or bacteria rather than individual pathogens. Around 200+ scientists from 53 countries are independently evaluating the evidence related to 30 viral families, one core group of bacteria, and "Pathogen X" – an unknown pathogen with the potential to trigger a severe global epidemic. This new approach will also help identify representative viruses (or prototypes) within a viral family as a pathfinder in generating evidence and filling knowledge gaps that may then apply to other viruses of threat in the same family.[^1] > > :[^1] <https://www.who.int/teams/blueprint/who-r-and-d-blueprint-for-epidemics> > > Improved pandemic preparedness could be achieved by proactively managing emerging virus threats focused on four discreet activities using currently available tools: > > - Discovery and surveillance, > - targeted basic research, > - translational research and product development, and > - clinical trial infrastructure and deployment capacity. > > Many have proposed a variety of approaches including promoting basic research, translational research, coordination of access to data, and development of prototype vaccines among others. Coordinating and accelerating global research must promote universal values. Regarding a collaborative effort to ensure access to MCMs during pandemics, some have emphasized the importance of speed and sometimes cost in responding to future pandemics. It is equally important to take a broader view that recognizes the primary importance of quality, equity in access, and trust in the products' safety and efficacy. As a community, we need to explore the different scientific challenges openly and broadly, discuss the scientific solutions being proposed; outline the various potential actions and what problem(s) each action will address.[^2] A series of four consultations have been planned to discuss these matters. > > :[^2] <https://cdn.who.int/media/docs/default-source/documents/r-d-blueprint-meetings/global-research-and-innovation-for-health-emergencies_report-2023.pdf> > > - Discovery and surveillance, > - To review the state of the art and the scientific opportunities and challenges > - To outline cross-cutting scientific actions are needed (globally and at the country level) to address the development challenges. > - To discuss and clarify the utility of establishing generalizable research approaches relative to specific product development within viral families. > > Many have proposed a variety of approaches including promoting basic research, translational research, coordination of access to data, and development of prototype vaccines among others. Coordinating and accelerating global research must pro > > | Meeting Dates | > |:---:| > |**First consultation – 9 January 2024**<br><br>A Scientific Framework for Epidemics and Pandemics Preparedness| > |**Second consultation – 18 January 2024**<br><br>Critical research for priority pathogens with epidemic potential| > |**Third consultation – 19 January 2024**<br><br>Research response to pathogen X during a pandemic| > |**Fourth consultation – February, 2024**<br><br>Addressing uncertainty during epidemics and pandemics by generating randomized evidence| > > Disclaimer - During these meetings, we will not discuss specific national or international initiatives or define or discuss the elements of global governance **PRESENTATIONS** **SCIENTIFIC APPROACHES TO ADDRESS UNCERTAINTY** - **Objectives of the Meeting**      [A scientific approach to pandemic preparedness](https://archive.org/details/a-scientific-approach-to-pandemic-preparedness) [A global effort to identify viral and bacterial families that are anticipated to threaten public health](https://archive.org/details/a-global-effort-to-identify-viral-and-bacterial-families-that-are-anticipated-to) %%<iframe src="https://archive.org/embed/a-scientific-approach-to-pandemic-preparedness" width="560" height="384" frameborder="0" webkitallowfullscreen="true" mozallowfullscreen="true" allowfullscreen></iframe> <iframe src="https://archive.org/embed/a-global-effort-to-identify-viral-and-bacterial-families-that-are-anticipated-to" width="560" height="384" frameborder="0" webkitallowfullscreen="true" mozallowfullscreen="true" allowfullscreen></iframe>%% **[Methods for Virus Detection and Discovery](https://cdn.who.int/media/docs/default-source/consultation-rdb/research-on-virus-detection-and-discovery-methods.pdf?sfvrsn=e1a82788_3)** <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/consultation-rdb/research-on-virus-detection-and-discovery-methods.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **[Peter Daszak - Smart Surveillance](https://cdn.who.int/media/docs/default-source/consultation-rdb/enhancing-unbiased-efforts-to-identify-new-pathogens_variants_strains-in-animals.pdf)** Enhancing unbiased efforts to identify new pathogens/ variants/strains in animals, including reservoir hosts, potential intermediate hosts, and common vectors <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/consultation-rdb/enhancing-unbiased-efforts-to-identify-new-pathogens_variants_strains-in-animals.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> **EXPANDING GENERALIZABLE BASIC RESEARCH THAT WOULD SUPPORT THE DEVELOPMENT OF VACCINES FOR FUTURE THREATS** [Using new technologies to define the atomic-level details of surface proteins likely to be vaccine targets](https://cdn.who.int/media/docs/default-source/consultation-rdb/using-new-technologies-to-define-the-atomic-level-details-of-surface-proteins-likely-to-be-vaccine-targets.pdf?sfvrsn=b15664e_5) [Understanding cell tropism and receptor requirements and determining replication mechanisms and capacity for antigenic diversity](https://cdn.who.int/media/docs/default-source/consultation-rdb/understanding-cell-tropism-and-receptor-requirements.pdf?sfvrsn=214e3ff_5) [Rapid development of monoclonal antibody and protein reagents to guide and facilitate vaccine development](https://cdn.who.int/media/docs/default-source/consultation-rdb/rapid-development-of-monoclonal-antibody-and-protein-reagents-to-guide-and-facilitate-vaccine-development.pdf?sfvrsn=9d52904f_5) [Developing humanized models with an eye on potential for generalizability - what needs to be done?](https://cdn.who.int/media/docs/default-source/consultation-rdb/developing-humanized-models-with-an-eye-on-potential-for-generalizability_what-needs-to-be-done.pdf?sfvrsn=42a57ca7_5) Developing humanized models with an eye on potential for generalizability: how to do it? [CRISPR/CAS9 as tool to improve animal models](https://cdn.who.int/media/docs/default-source/consultation-rdb/crispr_cas9-as-tool-to-improve-animal-models9e1f8aa6-63ab-4f70-b3f6-73aa7b639c11.pdf?sfvrsn=1405fc30_5) <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 60%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://cdn.who.int/media/docs/default-source/consultation-rdb/crispr_cas9-as-tool-to-improve-animal-models9e1f8aa6-63ab-4f70-b3f6-73aa7b639c11.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> [Humanized mice](https://cdn.who.int/media/docs/default-source/consultation-rdb/huminized-mice.pdf?sfvrsn=9311b87c_5) [Human organ on chip (MPS) infection model development](https://cdn.who.int/media/docs/default-source/consultation-rdb/human-organ-on-chip-(mps)-infection-model-development.pdf?sfvrsn=524431bd_5) [Introducing immunity to MPS](https://cdn.who.int/media/docs/default-source/consultation-rdb/introducing-immunity-to-mps-to-organ-chips-for-viral-diseases.pdf?sfvrsn=78d39377_5) [Developing immunological assays with an eye on potential for generalizability](https://cdn.who.int/media/docs/default-source/consultation-rdb/developing-immunological-assays.pdf?sfvrsn=6adc535b_5) **GLOBAL COLLABORATION TO COODINATE BASIC AND TRANSLATIONAL RESEARCH AS PART OF PANDEMIC PREPAREDNESS** [WHO R&D Blueprint for Epidemics](https://cdn.who.int/media/docs/default-source/consultation-rdb/who-r-d-blueprint-for-epidemics.pdf?sfvrsn=53e9a858_5) [WHO surveillance Hub](https://cdn.who.int/media/docs/default-source/consultation-rdb/who-surveillance-hub.pdf?sfvrsn=32b92a1d_5) **[Main conclusions](https://cdn.who.int/media/docs/default-source/consultation-rdb/who-meeting-summary.pdf?sfvrsn=91a6dc7b_3)** ##### Additional Documents & Resources [Celebrated virus hunter siphoned taxpayer funds for his 'Global Virome Project'](https://usrtk.org/covid-19-origins/celebrated-virus-hunter-siphoned-taxpayer-funds-for-his-private-global-virome-project/) > [!column|no-t flex bg-c-green]+ > %% You can insert iframes into the box.%% > > > [!info|no-icon bg-c-blue c-gray]- [Global Virome Project 2021 Emails](https://usrtk.org/wp-content/uploads/2021/05/GVP-State-Batch-3.pdf) <br> _{**Click to Expand ➜**} > > \- **[Archive](https://web.archive.org/web/20230417202657/http://usrtk.org/wp-content/uploads/2021/05/GVP-State-Batch-3.pdf)** > > > > <div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 80%;"><iframe src="https://docs.google.com/viewer?embedded=true&url=https://usrtk.org/wp-content/uploads/2021/05/GVP-State-Batch-3.pdf" style="top: 0; left: 0; width: 100%; height: 100%; position: absolute; border: 0;" allowfullscreen></iframe></div> %% FOOTER %% ---  --- ## Keep Digging %%Space%% ### Tags #Stream/BDE ### Footnotes & References